Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Expected to Rise, B. Riley Financial Analyst Says

Perspective Therapeutics (NYSEAMERICAN:CATX) had its target price lifted by analysts at B. Riley Financial from $11.00 to $13.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s price target points to a potential upside of 182.61% from the stock’s previous close.

A number of other brokerages also recently weighed in on CATX. HC Wainwright raised their price objective on Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, January 30th. UBS Group increased their price target on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday. Truist Financial set a $12.00 price target on shares of Perspective Therapeutics in a report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday. Finally, Piper Sandler started coverage on shares of Perspective Therapeutics in a research note on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $12.50.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $4.60 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 5.17. The business has a fifty day moving average of $4.34 and a two-hundred day moving average of $3.44. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. On average, research analysts predict that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Patient Square Capital LP acquired a new position in Perspective Therapeutics during the 3rd quarter valued at approximately $1,198,000. Siligmueller & Norvid Wealth Advisors LLC acquired a new stake in shares of Perspective Therapeutics during the third quarter worth $565,000. SG Americas Securities LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter valued at $46,000. Los Angeles Capital Management LLC purchased a new stake in shares of Perspective Therapeutics during the second quarter valued at $61,000. Finally, Avidity Partners Management LP increased its position in shares of Perspective Therapeutics by 7.2% in the 4th quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock valued at $8,830,000 after acquiring an additional 216,700 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics News Summary

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Several major firms raised ratings or price targets, which supports upside sentiment: B. Riley raised its price target to $13 and kept a Buy rating (large implied upside). UBS increased its target to $8 with a Buy. Wedbush reaffirmed an Outperform and a $11 target. Article Title
• Positive Sentiment: BTIG issued a Buy rating, adding to the cluster of bullish research that can attract momentum investors and buyers ahead of earnings. Article Title
• Positive Sentiment: Brookline Capital Markets (analyst K. Dolliver) raised EPS forecasts across Q1–Q4 2026 and lifted FY2026 from ($1.98) to ($1.27) — a meaningful reduction in projected losses vs their prior view. Incremental beat/less-bad guidance in analyst models tends to be supportive for the stock. Note Brookline’s FY view still implies a loss below consensus. Article Title
• Neutral Sentiment: Perspective announced a quarterly earnings release date (upcoming). Earnings will likely be the primary near-term catalyst and could swing the stock either way depending on clinical/program updates, cash burn, or guidance. Article Title
• Negative Sentiment: Royal Bank of Canada lowered expectations for CATX’s stock price, which may pressure sentiment among investors who follow bank research or use RBC’s view for risk management. Article Title

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.